| 别名 | CDKN2A;CDKN2;MLM;Cyclin-dependent kinase inhibitor 2A;isoform 4;p14ARF;p19ARF |
| 基因名称 | CDKN2A |
| 蛋白名称 | Cyclin-dependent kinase inhibitor 2A isoform 4 |
| 推荐应用 | |
| 反应物种 | Human, |
| 存储缓冲液 | PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA |
| Human Gene Link | 1029 |
| Human Swissprot No. | Q8N726 |
| Mouse Swissprot No. | Q64364 |
| 特异性 | endogenous |
| 稀释度 | WB 1:1000-1:2500；ELISA 1:5000-20000 |
| 参考分子量 | MW(Observed):16kD |
| 预测分子量 | MW(Calculated):14kD |
| 运输及保存条件 | -15°C to -25°C/1 year(Do not lower than -25°C) |
| 宿主 | Rabbit |
| 同种型 | IgG,Kappa |
| 背景介绍 | CDKN2A generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by CDKN2A, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. CDKN2A is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. |
| 细胞定位 | Nuclear |
| 纯化 | Protein A |
| Clonality | Monoclonal |
| 修饰类型 | Unmodified |
| 细胞定位 | Nuclear |
| 组织表达 | Testis, Thymus, Bone marrow, Lung cancer, Colon cancer, Breast cancer |
周一至周日 8:00-18:00
